{"title":"Hsp90 Inhibitors are Promising Radiosensitizers for Radiotherapy","authors":"N. Kubota, Y. Matsumoto","doi":"10.3191/THERMALMED.28.53","DOIUrl":null,"url":null,"abstract":"Heat shock protein 90(Hsp90)is an ATP-dependent molecular chaperone protein.The Hsp90 superchaperone complex assists folding and function of a variety of client proteins.Many oncoproteins are Hsp90 client proteins.Compared to normal cels,tumor cels require higher Hsp90 chaperone activity;therefore,targeting Hsp90 with chemical inhibitors disrupts multiple oncogenic processes and has potent antitumor activity.Many Hsp90 inhibitors are currently being tested in preclinical or clinical trials.This review summarizes published data concerning radiosensitization of human tumor cels in in vitro and in vivo tumor models with Hsp90 inhibitors.","PeriodicalId":23299,"journal":{"name":"Thermal Medicine","volume":"884 1","pages":"53-62"},"PeriodicalIF":0.0000,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thermal Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3191/THERMALMED.28.53","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Heat shock protein 90(Hsp90)is an ATP-dependent molecular chaperone protein.The Hsp90 superchaperone complex assists folding and function of a variety of client proteins.Many oncoproteins are Hsp90 client proteins.Compared to normal cels,tumor cels require higher Hsp90 chaperone activity;therefore,targeting Hsp90 with chemical inhibitors disrupts multiple oncogenic processes and has potent antitumor activity.Many Hsp90 inhibitors are currently being tested in preclinical or clinical trials.This review summarizes published data concerning radiosensitization of human tumor cels in in vitro and in vivo tumor models with Hsp90 inhibitors.